Neumora Therapeutics, Inc.
NMRANasdaq
$1.61
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +15.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$289.6M
Enterprise Value
$255.5M
P/E
—
P/S
—
P/B
4.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$251.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
355.8%
ROIC
-481.9%
Debt / Equity
1.6
Net Cash
$34.1M
Return 1Y
-5.9%
Company profile
We are a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts.
- CEO
- Henry O. Gosebruch
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- neumoratx.com
Management & directors
- Aurora Daljit SinghSee Remarks
- Berns Paul LSee Remarks
- Milligan Michael LeeSee Remarks
- Pinto JoshuaPresident
Roles derived from SEC Form 4 filings.
Earnings
NMRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.30↓ -28.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$135.9M | -$252.1M | -$263.5M | -$241.2M |
| Net income | -$130.9M | -$235.9M | $243.8M | $236.9M |
| Diluted EPS | -$4.81 | -$3.63 | -$1.53 | -$1.45 |
| Operating cash flow | -$114.9M | -$163.3M | -$182.9M | -$206.4M |
| Free cash flow | -$115.4M | -$163.4M | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$63.8M | -$76.6M | -$62.9M | -$70.9M | -$54.0M | -$57.7M | -$58.5M | -$52.9M |
| Net income | -$58.7M | -$72.5M | $428.8M | -$68.0M | -$52.7M | -$56.8M | $414.4M | -$53.5M |
| Diluted EPS | -$0.37 | -$0.45 | -$0.37 | -$0.42 | -$0.33 | -$0.35 | -$0.35 | -$0.30 |
| Operating cash flow | -$56.2M | -$33.5M | -$50.3M | -$59.4M | -$52.4M | -$46.6M | -$48.0M | -$46.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-17 | BERNS PAUL L· See Remarks | Sale | 9,819 | $3.51 | $34,458.80 | filing |
| 2026-02-17 | Aurora Daljit Singh· See Remarks | Sale | 6,165 | $3.56 | $21,916.58 | filing |
| 2026-02-17 | Pinto Joshua· President | Sale | 5,967 | $3.54 | $21,093.35 | filing |
| 2026-02-17 | Milligan Michael Lee· See Remarks | Sale | 1,436 | $3.57 | $5,119.34 | filing |
| 2025-11-11 | Aurora Daljit Singh· See Remarks | Sale | 114,703 | $2.68 | $307,025.52 | filing |
| 2025-10-27 | Burow Kristina | Buy | 1,915,700 | $2.61 | $5.0M | filing |
| 2025-10-27 | ARCH Venture Partners XII, LLC | Buy | 1,915,700 | $2.61 | $5.0M | filing |
| 2025-10-27 | ARCH Venture Partners X, LLC | Buy | 1,915,700 | $2.61 | $5.0M | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.